Cerebral Cavernous Malformations

About this condition

Cerebral cavernous malformations (CCM) are abnormal clusters of dilated blood vessels in the brain predisposed to hemorrhage. Familial CCM (approximately 50% of cases) follows autosomal dominant inheritance; the remaining cases involve single sporadic lesions. CCM manifests with hemorrhagic stroke, seizures, and progressive neurological deficits ranging from mild cognitive changes to severe disability. Hemorrhage rate for familial forms is approximately 0.7–1.1% per lesion per year. Three genes cause familial CCM: KRIT1 (encoding a scaffolding protein), CCM2, and PDCD10 (programmed cell death 10, an apoptosis-related protein). These proteins form the CCM complex regulating endothelial cell-cell adhesion and barrier function.

Familial CCM prevalence is estimated at 1 in 5,000 to 1 in 10,000 in Hispanic Americans due to founder mutation effects. KRIT1 mutations account for approximately 50% of familial CCM; CCM2 accounts for a minority; PDCD10 accounts for approximately 20% but is associated with a markedly more severe phenotype. Critically, PDCD10 mutations are associated with significantly more aggressive disease: earlier age of onset, greater number of lesions, higher hemorrhage rate, and additional manifestations including scoliosis and perioral skin lesions. Approximately 80% of carriers of a familial CCM variant develop detectable lesions by adulthood. Approximately 10–20% of familial CCM cases remain genetically unresolved, suggesting additional undiscovered genes.

A pathogenic variant in KRIT1, CCM2, or PDCD10 confirms familial CCM and mandates surveillance of all first-degree relatives with brain MRI — approximately 80% of carriers develop detectable lesions by adulthood. Genotype-phenotype correlation is critical: PDCD10-positive families should expect more aggressive disease with earlier onset, more lesions, higher hemorrhage risk, and additional systemic manifestations. These patients require closer neuroradiologic surveillance and lower thresholds for surgical intervention. Symptomatic CCM lesions (those causing seizures or hemorrhage) warrant neurosurgical evaluation; asymptomatic superficial lesions may be monitored conservatively. Genetic diagnosis enables genetic counseling and cascade family screening, identifying at-risk presymptomatic carriers who benefit from surveillance protocols.

PDCD10 mutations cause significantly more aggressive disease with earlier onset, greater lesion burden, higher hemorrhage rates, and additional systemic manifestations like scoliosis and perioral skin changes.

Gene locus: KRIT1 (7q21.2), CCM2 (7p13), PDCD10 (3q26.1)

CCM genetic testing is underutilized despite high value for family surveillance. 10–20% of familial cases remain genetically unresolved, suggesting additional genes.

Genetic testing distinguishes familial CCM from sporadic lesions — critical for family surveillance

CCM genetic testing targeting the three major genes is available through specialized neurology genetic panels, but many centers do not routinely offer it — resulting in significant underdiagnosis of familial disease. Approximately 10–20% of familial CCM cases remain genetically unresolved despite comprehensive testing, suggesting additional undiscovered genes. Genetic testing is critical for distinguishing familial disease (requiring surveillance of at-risk relatives) from truly sporadic lesions. A single patient with a pathogenic variant implies that approximately 50% of first-degree relatives carry the variant and should receive surveillance MRI. Whole genome sequencing enables simultaneous evaluation of all three major genes and potential novel genes.

Genotype predicts disease severity and family screening urgency

A pathogenic variant in KRIT1, CCM2, or PDCD10 confirms familial CCM and mandates family cascade screening with brain MRI. Genotype-phenotype correlation is critical: PDCD10-positive families should expect significantly more aggressive disease with earlier symptom onset, greater lesion burden, and higher hemorrhage rates — warranting more intensive surveillance and lower thresholds for surgical intervention. KRIT1 and CCM2 families typically show milder disease courses. Approximately 80% of carriers develop detectable lesions by adulthood. Early detection through surveillance enables identification of lesions before hemorrhage occurs, preventing catastrophic neurological events.

A brain MRI found something unexpected. Or a family member had one too. Understanding the genetic cause turns an uncertain finding into a clear surveillance plan.